Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE): Study Design of a Prospective Observational Registry

Joseph Jankovic1, Mark Stacy2, David Charles3, Charles H Adler4, Cynthia Comella5, Mitchell Brin6,7, Spyridon Papapetropoulos6,8 (on behalf of the CD PROBE Study Group)

1Baylor College of Medicine, Houston, TX; 2Duke University Medical Center, Durham, NC; 3Vanderbilt University Medical Center, Nashville, TN; 4Mayo Clinic, Scottsdale, AZ; 5Rush University Medical Center, Chicago, IL; 6Allergan, Inc, Irvine, CA; 7University of California, Irvine, CA; 8University of Miami, Miller School of Medicine, Miami, FL.

CD PROBE is the largest observational study of CD treatment. Baseline demographics indicate that the cohort is representative of the general CD population.

4. Work productivity assessment at baseline

5. Effect of CD on work productivity

6. Change in work productivity

7. Change in productivity

CONCLUSIONS

CD PROBE is the largest observational study of CD treatment. Baseline demographics indicate that the cohort is representative of the general CD population. Work productivity assessment at baseline demonstrated that CD affected employment status, led to missed work days, and was associated with decreased productivity. The registry will provide clinical data on current treatment practices as well as physician and patient assessments of treatment with onabotulinumtoxinA, with the ultimate goal of improving outcomes for patients with CD.

REFERENCES


